From the publishers of JADPRO
CAR T-Cell Therapy
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge on ICANS management in patients receiving CAR T-cell therapy
Last Updated: Friday, April 7, 2023
Loading...
Advertisement
News & Literature Highlights
Future Oncology
Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable
Blood
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy
EBioMedicine
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Diagnostics (Basel)
CAR-T cell therapy in ovarian cancer: Where are we now?
U.S. Food and Drug Administration
FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies
Journal for ImmunoTherapy of Cancer
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors
Nature Reviews Immunology
In vivo CAR engineering for immunotherapy
Seminars in Arthritis and Rheumatism
Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies—evidence, safety, and future directions
Blood Advances
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
Blood Advances
Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis
Advertisement
Case Studies
Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma
Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy
Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy
Fast Facts
Fast Facts #12: BCMA Targets
Advertisement
Quizzes
Test your knowledge of hemophagocytic lymphohistiocytosis following CAR T-cell therapy in a patient with multiple myeloma
Test your knowledge of bloodless medicine management of a patient receiving CAR T-cell therapy
Test your knowledge of atypical manifestation of neurotoxicity following CAR T-cell therapy